scholarly journals A randomized, placebo- and sitagliptin-controlled trial of the safety and efficacy of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes

2017 ◽  
Vol 19 (11) ◽  
pp. 1602-1609 ◽  
Author(s):  
Ira Gantz ◽  
Taro Okamoto ◽  
Yuka Ito ◽  
Kotoba Okuyama ◽  
Edward A. O'Neill ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Controlled Trial ◽  
Japanese Patients ◽  
Dipeptidyl Peptidase ◽  
Safety And Efficacy ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitor

Long-term safety, tolerability, and efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes

2011 ◽  
Vol 2 (2) ◽  
pp. 94-105 ◽  
Author(s):  
Masato Odawara ◽  
Takashi Kadowaki ◽  
Naoko Tajima ◽  
Mikio Nishii ◽  
Tadaaki Taniguchi ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Japanese Patients ◽  
Dipeptidyl Peptidase ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitor
Sign in / Sign up

Export Citation Format

Share Document